BIOFRONTERA
PharmaBIOFRONTERA is a pharmaceutical company focused on Oncology, Dermatology. Key products include AMELUZ.
BIOFRONTERA at a Glance
- Strong track record with 100% execution quality across 5 trials
- Fast trial execution (17 months median completion)
Upcoming FDA Decisions
Full Calendar →BIOFRONTERA's Key Drugs
BIOFRONTERA's core commercial portfolio centers on AMELUZ, spanning Oncology and Dermatology — its most strategically important drugs approved in the last 15 years.
BIOFRONTERA's Recent FDA Approvals
New NDA/BLA approvals for BIOFRONTERA over the last two years — novel drugs only, excluding generics and label supplements.
BIOFRONTERA's Therapeutic Areas
BIOFRONTERA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BIOFRONTERA's Top Competitors
BIOFRONTERA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BIOFRONTERA Pipeline Snapshot
BIOFRONTERA has 3 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • AMELUZ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/3 completed
- • Speed: 17 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2000-11-27
- Latest
- 2026-09-09
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges